血清基质溶素水平可预测接受根治性切除的结直肠癌患者的预后。
Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.
作者信息
Martínez-Fernandez Alejandro, García-Albeniz Xabier, Pineda Estela, Visa Laura, Gallego Rosa, Codony-Servat Jordi, Augé Josep Maria, Longarón Raquel, Gascón Pere, Lacy Antonio, Castells Antoni, Maurel Joan
机构信息
Department of Medical Oncology, Hospital Clínic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Centro de Investigación Médica de Enfermedades Hepáticas y Digestivas, University of Barcelona, Barcelona, Catalonia, Spain.
出版信息
Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9. Epub 2009 Mar 4.
BACKGROUND
Matrix metalloproteinase 7 (MMP-7) is involved in invasion, metastasis, growth, and angiogenesis. The aim of this study is to assess the prognostic role of serum MMP-7 in curatively resected colorectal cancer (CRC).
MATERIALS AND METHODS
Patients undergoing resection for CRC (n = 175) were recruited from July 2003 to December 2004. MMP-7 was determined using a quantitative solid phase sandwich ELISA. Cox analysis was used to assess the role of MMP-7 in predicting overall survival (OS) and disease-free survival (DFS).
RESULTS
The median length of follow-up was 45 months (range 1 to 59). Levels of MMP-7 are predictors of DFS (hazard ratio [HR] 1.119, 95% confidence interval [95% CI] 1.038-1.207) and of OS (HR 1.113, 95% CI 1.025-1.209). Patients with MMP-7 higher than the median (4.3 ng/ml) are more likely to relapse (29.5% vs 18.4%, P = .084); median time to progression in relapsed patients is 8 months if MMP-7 is > or =4.3 ng/ml and 18 months if MMP-7 is <4.3 ng/ml. Node-negative patients with low MMP-7 have a predicted probability of relapse-free survival at 4 years of 88% (95% CI 83-92%); if the MMP-7 is higher than the median value; this probability is 77% (95% CI 73-81%).
CONCLUSION
MMP-7 predicts recurrence in curatively resected CRC patients.
背景
基质金属蛋白酶7（MMP - 7）参与侵袭、转移、生长和血管生成。本研究旨在评估血清MMP - 7在根治性切除的结直肠癌（CRC）中的预后作用。
材料与方法
2003年7月至2004年12月招募了接受CRC切除术的患者（n = 175）。使用定量固相夹心酶联免疫吸附测定法测定MMP - 7。采用Cox分析评估MMP - 7在预测总生存期（OS）和无病生存期（DFS）中的作用。
结果
中位随访时间为45个月（范围1至59个月）。MMP - 7水平是DFS（风险比[HR] 1.119，95%置信区间[95% CI] 1.038 - 1.207）和OS（HR 1.113，95% CI 1.025 - 1.209）的预测指标。MMP - 7高于中位数（4.3 ng/ml）的患者更易复发（29.5%对18.4%，P = 0.084）；复发患者中，若MMP - 7≥4.3 ng/ml，进展的中位时间为8个月；若MMP - 7＜4.3 ng/ml，则为18个月。MMP - 7低的淋巴结阴性患者4年无复发生存的预测概率为88%（95% CI 83 - 92%）；若MMP - 7高于中位数，该概率为77%（95% CI 73 - 81%）。
结论
MMP - 7可预测根治性切除的CRC患者的复发情况。
Zotero 插件